• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Spruce Biosciences Inc.

    4/28/25 4:10:03 PM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SPRB alert in real time by email
    DEFA14A 1 sprb-defa14a-2025-final.htm DEFA14A DEFA14A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A INFORMATION

     

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

    ☐ Preliminary Proxy Statement

    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐ Definitive Proxy Statement

    ☒ Definitive Additional Materials

    ☐ Soliciting Material Pursuant to §240.14a-12

    Spruce Biosciences, Inc.

    (Name of Registrant as Specified In Its Charter)

    N/A

    (Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

    ☒ No fee required.

    ☐ Fee paid previously with preliminary materials

    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     


     

    img235890869_0.jpg

    Logo sprucebio SPRUCE BIOSCIENCES, INC. 611 GATEWAY BOULEVARD, SUITE 740 SOUTH SAN FRANCISCO, CA 94080 Your Vote Counts! SPRUCE BIOSCIENCES, INC. 2025 Annual Meeting Vote by June 8, 2025 11:59 PM ET V74239-P30195 You invested in SPRUCE BIOSCIENCES, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the annual stockholder meeting to be held on June 9, 2025 at 10:00 a.m. Pacific Timeat www.virtualshareholdermeeting.com/SPRB2025 and any adjournment or postponement thereof. Get informed before you vote View the Notice of Annual Meeting, Proxy Statement and Annual Report on Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 26, 2025. To view the voting material(s) online, visit www.ProxyVote.com and have your control number (indicated below) available. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. Logo pv For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Vote Virtually at the Meeting* June 9, 2025 10:00 AM PDT Virtually at: www.virtualshareholdermeeting.com/SPRB2025 *Please check the meeting materials for any special requirements for meeting attendance.


    img235890869_1.jpg

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting as described in more detail in the complete proxy materials available to you online. You may view the proxy materials online at ProxyVote.com or easily request a paper copy (see reverse side). Please follow the instructions on the reverse side to vote these important matters. Before voting, we encourage you to access and review all of the important information contained in the proxy materials. Voting Items Board Recommends 1. To elect the three Class II directors named below to hold office until the Company’s 2028 annual meeting of stockholders. Nominees: 01) Percival Barretto-Ko 02) Bali Muralidhar, M.D., Ph.D. 03) Daniel Spiegelman For 2. To ratify the selection by the Audit Committee of the Board of Directors (the “Board”) of BDO USA, P.C. as the independent registered public accounting firm of the Company for the Company’s fiscal year ending December 31, 2025. For 3. To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split (the “Reverse Stock Split”) of the Company’s common stock by a ratio of between one-for-five and one-for-thirty, with the exact ratio to be determined by the Board in its sole discretion and with such Reverse Stock Split to be effected at such time and date, if at all, as determined by the Board in its sole discretion. For 4. To approve the adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal 3. For NOTE: In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting or any adjournments or postponements thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V74240-P30195


    Get the next $SPRB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SPRB

    DatePrice TargetRatingAnalyst
    12/11/2024Mkt Outperform → Mkt Perform
    JMP Securities
    12/11/2024Outperform → Perform
    Oppenheimer
    3/14/2024Buy → Neutral
    Guggenheim
    3/14/2024$9.00 → $2.00Outperform → Market Perform
    Leerink Partners
    3/14/2024$9.00 → $2.00Outperform → Sector Perform
    RBC Capital Mkts
    3/14/2024Buy → Neutral
    Ladenburg Thalmann
    3/14/2024Buy → Neutral
    H.C. Wainwright
    2/21/2024$10.00Buy
    Guggenheim
    More analyst ratings

    $SPRB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Spruce Biosciences Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital Market

      Relisting Contingent Upon Stockholder Approval of Reverse Stock Split Trading on Nasdaq Capital Market Anticipated to Commence On or Before August 5, 2025 Spruce Biosciences, Inc. (OTC:SPRB) ("Spruce"), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, announced that it has received approval from The Nasdaq Stock Market LLC ("Nasdaq") to resume trading of its common stock on the Nasdaq Capital Market subject to Spruce regaining compliance with Nasdaq's minimum bid price requirement on or before August 5, 2025. "We are pleased by Nasdaq's decision to lift its trading suspensio

      6/12/25 8:00:00 AM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

      Acquisition of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) Biologics License Application (BLA) Submission to U.S. FDA for TA-ERT Expected in 1H 2026 Spruce Biosciences, Inc. (OTC:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2025 and provided corporate updates. "With no FDA-approved treatments currently available to treat MPS IIIB, TA-ERT has the potential to be a groundbreaking advancement for patients and families impacted by t

      5/6/25 4:01:00 PM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

      Biologics License Application (BLA) Submission to U.S. FDA for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Anticipated in 1H 2026 Spruce to Host Conference Call Today at 8:30 a.m. ET Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the company's new corporate strategy and acquisition of tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB). "This is truly a transformative moment for Spruce as we focus our expertise in rare disease on a potential near-te

      4/15/25 7:00:00 AM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Spruce Biosciences downgraded by JMP Securities

      JMP Securities downgraded Spruce Biosciences from Mkt Outperform to Mkt Perform

      12/11/24 8:25:53 AM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spruce Biosciences downgraded by Oppenheimer

      Oppenheimer downgraded Spruce Biosciences from Outperform to Perform

      12/11/24 8:25:37 AM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spruce Biosciences downgraded by Guggenheim

      Guggenheim downgraded Spruce Biosciences from Buy to Neutral

      3/14/24 8:20:07 AM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF MEDICAL OFFICER Charlton Ralph William Iii converted options into 164,750 shares and covered exercise/tax liability with 58,784 shares, increasing direct ownership by 191% to 161,339 units (SEC Form 4)

      4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)

      12/20/24 8:30:02 PM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRESIDENT AND CFO Gharib Samir M. converted options into 229,750 shares and covered exercise/tax liability with 81,976 shares, increasing direct ownership by 73% to 350,550 units (SEC Form 4)

      4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)

      12/20/24 8:28:58 PM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF EXECUTIVE OFFICER Szwarcberg Javier B. converted options into 559,500 shares and covered exercise/tax liability with 199,630 shares, increasing direct ownership by 335% to 467,191 units (SEC Form 4)

      4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)

      12/20/24 8:28:11 PM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRB
    SEC Filings

    See more
    • Spruce Biosciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

      8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)

      6/12/25 8:10:45 AM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Spruce Biosciences Inc.

      DEFA14A - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)

      6/12/25 8:05:03 AM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Spruce Biosciences Inc.

      DEFA14A - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)

      6/6/25 4:10:04 PM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRB
    Leadership Updates

    Live Leadership Updates

    See more
    • Spruce Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

      Spruce Reports Interim Data from Phase 2 POWER Proof-of-Concept Study in Polycystic Ovary Syndrome (PCOS) CAHmelia Program in Adult Classic Congenital Adrenal Hyperplasia (CAH) Surpasses 75% Enrollment in CAHmelia-203 and Approaches 75% Enrollment in CAHmelia-204 Screening Underway for Cohort 3 in CAHptain Study for Pediatric Classic CAH Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2023 and provided corporate updates. "Our goal with the POWER study is to ass

      8/14/23 4:00:00 PM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spruce Biosciences Appoints Percival Barretto-Ko to Board of Directors

      Accomplished life sciences industry executive brings more than 20 years of commercial and biopharmaceutical expertise to Spruce Board Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced the appointment of Percival Barretto-Ko to the company's Board of Directors. Concurrently, Dina Chaya, Ph.D., has stepped down from the Board of Directors. "On behalf of Spruce, I am pleased to welcome Percival Barretto-Ko to our Board of Directors," said Mike Grey, Executive Chairman of Spruce Biosciences. "Percival is an accomplished and

      5/25/23 8:00:00 AM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spruce Biosciences Reports First Quarter 2023 Financial Results and Provides Corporate Updates

      CAHmelia Program in Adult Classic Congenital Adrenal Hyperplasia (CAH) Achieves 50% Enrollment in CAHmelia-204 and Approaches 75% Enrollment in CAHmelia-203 Enrollment in P.O.W.E.R. Study for Polycystic Ovary Syndrome (PCOS) Complete – Topline Results Anticipated in Q3 2023 Cohort 1 for Phase 2 CAHptain Study in Pediatric Classic CAH Fully Enrolled Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the quarter ended March 31, 2023 and provided corporate updates. "I am pleased by the meaningful pro

      5/15/23 8:00:00 AM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRB
    Financials

    Live finance-specific insights

    See more
    • Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

      Biologics License Application (BLA) Submission to U.S. FDA for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Anticipated in 1H 2026 Spruce to Host Conference Call Today at 8:30 a.m. ET Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the company's new corporate strategy and acquisition of tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB). "This is truly a transformative moment for Spruce as we focus our expertise in rare disease on a potential near-te

      4/15/25 7:00:00 AM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

      CAHmelia-203 Study of Tildacerfont in Adult Classic Congenital Adrenal Hyperplasia (CAH) with Severe Hyperandrogenemia Did Not Meet Primary Efficacy Endpoint Positive Data from CAHptain-205 Study of Tildacerfont in Pediatric Classic CAH Supports Further Dose-Ranging Across Additional Dosing Cohorts Topline Results from CAHmelia-204 Study of Tildacerfont in Adult Classic CAH Evaluating Glucocorticoid (GC) Reduction Anticipated in Third Quarter of 2024 Resource Prioritization and Cost Reductions Extend Cash Runway Through End of 2025 Conference Call Today at 4:30 p.m. ET Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commerci

      3/13/24 4:08:00 PM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Spruce Biosciences Inc.

      SC 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)

      11/14/24 5:45:17 PM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Spruce Biosciences Inc.

      SC 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)

      11/14/24 4:39:47 PM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Spruce Biosciences Inc.

      SC 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)

      11/12/24 4:10:36 PM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care